EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Safety of Short-course Weekly Rifapentine and Isoniazid (3HP) for TB Preventive Treatment at Conception and During First Trimester in Women With HIV: A Secondary Analysis of the WHIP3TB trial

Violet Chihota iD, Zainab Waggie, Vicky Cardenas iD, Kathy Mngadi iD, Felex Ndebele iD, William Brumskine iD, Modulakgotla Sebe, Neil Martinson iD, Shu-Hua Wang iD, Getnet Yimer, Dinis Nguenha iD, Alberto L Garcia-Basteiro iD und 7 weitere

Clinical Infectious Diseases · 2026

DOI: 10.1093/cid/ciag315 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Infectious Diseases, 2026. Verfasst von Violet Chihota und 18 weiteren Autor:innen. Beteiligte Einrichtung: Research Division, The Aurum Institute, Johannesburg, South Africa. Hauptthemen laut MEDLINE: Rifampin, Isoniazid, HIV Infections, Antitubercular Agents. Die Arbeit nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: USAID.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The safety of a 3-month weekly rifapentine-isoniazid (3HP) for tuberculosis prevention in HIV-positive pregnant women on antiretroviral treatment is unknown. As part of the WHIP3TB trial, 3HP administered once or annually for 2 years was compared to 6 months of isoniazid. We report outcomes among women who became pregnant, with drug exposure in early pregnancy.

Methods

Women were classified as exposed if conception occurred while taking study drug, and unexposed if conception occurred after the last dose. Outcomes included live birth, stillbirth, or abortion. A composite adverse pregnancy outcome was defined as any of the following: stillbirth, spontaneous abortion, low birth weight (<2500 g), preterm delivery (<37 weeks’ gestation), or major congenital anomalies. Outcomes were compared between exposed and unexposed groups.

Results

Among 2207 women aged 15–49 years enrolled between November 2016 and November 2017, 236 pregnancies occurred in 222 participants. Fifty-seven (24%) were exposed to study drug (51 in 3HP arm, 6 in 6 months of isoniazid arm) and 179 were unexposed. Median age was 32 years, median antiretroviral treatment duration 2.9 years (interquartile range; 1.2–4.9 years) and median CD4 count 522 cells/L; [interquartile range, 345–684). Of 219 pregnancies with known outcomes, 162 (74%) were live births, 51 (23%) abortions, and 6 (3%) stillbirths. Spontaneous abortions occurred at similar frequencies among exposed (12% [7/57]) and unexposed (14% [22/162]) groups with comparable rates of composite adverse outcomes (33% [19/57] vs 35% [56/162]).

Conclusions

Spontaneous abortion and composite adverse pregnancy outcomes following first-trimester exposure to 3HP were comparable between exposed and unexposed groups, supporting the safety of 3HP in pregnancy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

RifampinIsoniazidHIV InfectionsAntitubercular AgentsPregnancy Complications, InfectiousTuberculosisHumansFemalePregnancyAdultPregnancy Trimester, FirstPregnancy OutcomeAdolescentYoung AdultMiddle AgedAbortion, Spontaneous

Stichwörter der Autor:innen

HIVTBTB preventive treatmentpregnancyrifapentine

Substanzen

RifampinrifapentineIsoniazidAntitubercular Agents

Autor:innen und Institutionen

  • Research Division, The Aurum Institute, Johannesburg, South Africa.
  • School of Public Health, University of Witwatersrand, Johannesburg, South Africa.
  • Department of Medicine, Vanderbilt University, Nashville, Tennessee, USA.
  • Perinatal HIV Research Unit (PHRU), Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.
  • Division of Infectious Disease, Department of Internal Medicine, The Ohio State University Global One Health Initiative, College of Medicine, Columbus, Ohio, USA.
  • Center for Global Genomics and Health Equity, Department of Genetics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, pennsylvania, USA.

ORCID-Profile: Violet Chihota, Vicky Cardenas, Kathy Mngadi, Felex Ndebele, William Brumskine, Neil Martinson, Shu-Hua Wang, Dinis Nguenha, Alberto L Garcia-Basteiro, Susan van den Hof, Salome Charalambous, Katherine L Fielding, Gavin Churchyard

Förderung

  • USAID

Zitieren

APA

Chihota, V., Waggie, Z., Cardenas, V., Mngadi, K., Ndebele, F., Brumskine, W., Sebe, M., Martinson, N., Wang, S. H., Yimer, G., Nguenha, D., Garcia-Basteiro, A. L., van den Hof, S., Grant, A. D., Charalambous, S., Fielding, K. L., Chaisson, R. E., Churchyard, G., & WHIP3TB study team (2026). Safety of Short-course Weekly Rifapentine and Isoniazid (3HP) for TB Preventive Treatment at Conception and During First Trimester in Women With HIV: A Secondary Analysis of the WHIP3TB trial. Clinical Infectious Diseases. https://doi.org/10.1093/cid/ciag315

Vancouver

Chihota V, Waggie Z, Cardenas V, Mngadi K, Ndebele F, Brumskine W, et al. Safety of Short-course Weekly Rifapentine and Isoniazid (3HP) for TB Preventive Treatment at Conception and During First Trimester in Women With HIV: A Secondary Analysis of the WHIP3TB trial. Clinical Infectious Diseases. 2026. doi:10.1093/cid/ciag315

BibTeX
@article{Chihota2026,
  author = {Chihota, Violet and Waggie, Zainab and Cardenas, Vicky and Mngadi, Kathy and Ndebele, Felex and Brumskine, William and Sebe, Modulakgotla and Martinson, Neil and Wang, Shu-Hua and Yimer, Getnet and Nguenha, Dinis and Garcia-Basteiro, Alberto L and van den Hof, Susan and Grant, Alison D and Charalambous, Salome and Fielding, Katherine L and Chaisson, Richard E and Churchyard, Gavin and WHIP3TB study team, WHIP3TB study team},
  title = {Safety of Short-course Weekly Rifapentine and Isoniazid (3HP) for TB Preventive Treatment at Conception and During First Trimester in Women With HIV: A Secondary Analysis of the WHIP3TB trial},
  journal = {Clinical Infectious Diseases},
  year = {2026},
  doi = {10.1093/cid/ciag315}
}
Kostenlos starten →